Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Biosimilars Market from 2024 to 2025?#_x000D_

Over the past several years, the biosimilars market has experienced a significant surge. The market value is expected to rise from $18.65 billion in 2024 to $21.95 billion in 2025, equating to a compound annual growth rate (CAGR) of 17.7%. The remarkable expansion during the historical period can be attributed to factors such as the increased incidences of cancer, robust economic development in emerging markets, a hike in R&D spending in the pharmaceutical sector, increased healthcare expenditure, expanded government initiatives, a robust lineup of pharmaceutical products in the pipeline, reasonable pricing of biosimilars and an escalation in patent expirations._x000D_

_x000D_

#What Is the Projected Market Size of the Biosimilars Market?#_x000D_

The biosimilars market is poised to experience significant expansion in the coming years, ballooning to the tune of $42.16 billion by 2029, and at a compound annual growth rate (CAGR) of 17.7%. This predicted growth within the projection period can be credited to a combination of factors such as the rising occurrence of cancer, growing need for prophylaxis with granulocyte colony-stimulating factor (G-CSF), an upsurge in healthcare expenditure, the high promise of up-and-coming economies, advancements in technology, prevalent use of biological drugs, an ageing demographic, and enhanced access to healthcare. Key trends for this forecast period encompass an emphasis on vigorous R&D activities aimed at crafting effective and cutting-edge drugs, a focus on mergers and acquisitions growth strategies, establishing strategic alliances, ramping up investments, and leveraging artificial intelligence._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp_x000D_

_x000D_

#Who are the Major Competitors in the Biosimilars Market Outlook?#_x000D_

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)_x000D_

_x000D_

#What Is Fueling Growth in the Biosimilars Market?#_x000D_

The escalating incidences of long-term illnesses such as arthritis, asthma, and cancer are predicted to serve as a significant catalyst to the biosimilars market. Extended working schedules, inadequate physical exercise, coupled with poor nutrition, and excessive consumption of alcohol and other harmful substances often lead to the surge of chronic illnesses. These diseases are increasingly managed using biosimilars. Biosimilars stimulate the reaction of the immune system against cancer cells, aiding the body in getting rid of these cells. A United Nations report forecasts that by 2030, chronic illnesses will account for 70% of global fatalities. The overall chronic disease burden is expected to hit around 60%. Consequently, the escalating incidences of chronic illnesses are anticipated to spur the demand for biosimilars, thereby fueling the growth of the biosimilars market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp_x000D_

_x000D_

#Which Biosimilars Market Segments Are Growing the Fastest?#_x000D_

The biosimilars market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others_x000D_

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins_x000D_

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars_x000D_

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars_x000D_

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars_x000D_

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars_x000D_

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars_x000D_

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics_x000D_

_x000D_

_x000D_

#Which Industry Trends Are Shaping the Future of the Biosimilars Market?#_x000D_

In an effort to establish a competitive edge in the biosimilars market, major companies are concentrating on the creation of innovative products. More than a million patients suffering from certain severe inflammatory diseases use Amgen Inc.’s AMJEVITA, a US-based biotech firm’s debut biosimilar to Humira in the United States. As of January 2023, AMJEVITA (adalimumab-atto) was launched as a biosimilar to Humira (adalimumab) and became available in the US market. The list price (wholesale procurement cost) of AMJEVITA (40 mg) is 55% lower than the current list price of Humira, and it is also available at a price 5% less than Humira’s current list price._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report_x000D_

_x000D_

#Which Countries Are Leading the Biosimilars Market?#_x000D_

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the biosimilars market, and how is it changing globally?_x000D_

2. Who are the major companies in the biosimilars market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the biosimilars market right now?_x000D_

4. Which products or customer segments are growing the most in the biosimilars market?_x000D_

5. What factors are helping or slowing down the growth of the biosimilars market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model